92 related articles for article (PubMed ID: 16166324)
1. Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice.
Tabuchi M; To H; Sakaguchi H; Goto N; Takeuchi A; Higuchi S; Ohdo S
Cancer Res; 2005 Sep; 65(18):8448-54. PubMed ID: 16166324
[TBL] [Abstract][Full Text] [Related]
2. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
4. Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice.
To H; Shin M; Tabuchi M; Sakaguchi H; Takeuchi A; Matsunaga N; Higuchi S; Ohdo S
Clin Cancer Res; 2004 Jan; 10(2):762-9. PubMed ID: 14760099
[TBL] [Abstract][Full Text] [Related]
5. Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice.
Kodama A; To H; Kinoshita T; Ieiri I; Higuchi S
J Pharm Pharmacol; 2009 May; 61(5):615-21. PubMed ID: 19406000
[TBL] [Abstract][Full Text] [Related]
6. Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats.
To H; Ohdo S; Shin M; Uchimaru H; Yukawa E; Higuchi S; Fujimura A; Kobayashi E
J Pharm Pharmacol; 2003 Jun; 55(6):803-10. PubMed ID: 12841941
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
8. [Construction of optimal combined chemotherapy of anti-tumor drugs based on chronotherapy].
To H
Yakugaku Zasshi; 2006 Jun; 126(6):415-22. PubMed ID: 16755128
[TBL] [Abstract][Full Text] [Related]
9. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
10. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
12. Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity.
Sakaguchi H; Kodama A; Tomonari M; Ando Y; Tabuchi M; To H; Araki R; Kitahara T; Sasaki H; Ohdo S; Higuchi S
Breast Cancer Res Treat; 2008 Jun; 109(3):443-50. PubMed ID: 17661173
[TBL] [Abstract][Full Text] [Related]
13. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
14. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity.
Tomonari M; To H; Nishida M; Mishima T; Sasaki H; Kurose H
J Pharmacol Sci; 2011; 115(3):336-45. PubMed ID: 21358119
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
[TBL] [Abstract][Full Text] [Related]
17. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
[TBL] [Abstract][Full Text] [Related]
19. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
